Information Provided By:
Fly News Breaks for November 26, 2019
Nov 26, 2019 | 06:28 EDT
La Jolla Pharmaceutical (LJPC), a Protagonist Therapeutics (PTGX) competitor, announced yesterday that it will reassess development of LJPC-401, its synthetic human hepcidin formulation, due to mixed clinical results, Nomura Instinet analyst Christopher Marai tells investors in a research note. The analyst views the news positively for Protagonist's competing drug, PTG-300. He keeps a Buy rating on Protagonist shares with a $29 price target.
News For PTGX;LJPC From the Last 2 Days
There are no results for your query PTGX;LJPC